CTOs on the Move

APAC Partners

www.apacpartners.com

 
APAC Partners is a Dyer, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 5K-10K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details

Similar Companies

Asset Health

Asset Health is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sunrider

Sunrider offers an extraordinary opportunity to own a franchise-like business for a minimal cost. We have invested hundreds of millions of dollars in our global operations to provide you with exceptional support. We research, develop, and manufacture high quality herbal products in our 2 million square foot state-of-the-art manufacturing facilities.

GROVE INSTRUMENTS

GROVE INSTRUMENTS is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Worcester, MA. To find more information about GROVE INSTRUMENTS, please visit www.groveinstruments.com

Nucon International Inc

Nucon International Inc is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.